Skip to main content

Table 4 Changes in biomarkers and magnetic resonance imaging (MRI)

From: Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

Patientnumber

MRI response

pHER2 reduction

pERK1 reduction

MRI-pHER2 correlation

MRI-pERK1 correlation

1

No Change*

NA

No

NA

NA

2

PR

No

No

No

No

3

PR

Yes

Yes

Yes

Yes

4

PR

Yes

No

Yes

No

5

No change*

NA

NA

NA

NA

6

No change*

NA

NA

NA

NA

7

No change*

No

No

NA

NA

8

PR

No

No

No

No

9

PR

Yes

No

Yes

No

10

PR

Yes

No

Yes

No

11

PR

NA

NA

No

No

12

No change*

NA

No

NA

NA

13

No change*

NA

NA

NA

NA

14

SD

Yes

No

No

No

15

No change*

Yes

Yes

NA

NA

16

SD

No

No

No

No

17

PR

Yes

Yes

Yes

Yes

18

PR

Yes

No

Yes

No

19

No change*

Yes

Yes

NA

NA

20

SD

No

No

No

No

  1. pHER2, phospho human epidermal growth factor receptor 2; pERK1, phosphor extracellular-regulated kinase 1; SD, stable disease (response evaluation criteria in solid tumors (RECIST) criteria); NA, not applicable; PR, partial response (RECIST criteria); no change*, patients with Breast Imaging Reporting and Data System (BIRADS)-2 at diagnosis.